Regardless of type 1 or type 2 diabetes, early glycemic control can effectively reduce the risk of long-term complications. Insulin therapy has a powerful hypoglycemic effect, and the “basal insulin + mealtime insulin” regimen has been widely used for glycemic control in patients with diabetes. However, the pharmacokinetic and pharmacodynamic properties of basal insulin, hypoglycemia, weight gain and the complexity of dosing have limited its full clinical application. As a new type of basal insulin, degludec insulin has more favorable pharmacokinetic and pharmacodynamic properties than glargine insulin. The half-life of degludec insulin is close to 25 hours, and the steady-state blood concentration duration of action is more than 42 hours, and it can exert long-lasting and stable glucose-lowering effects with one injection per day. Attainment trials in type 1 and type 2 diabetes have shown similar efficacy of degludec insulin and glargine insulin, with a significant reduction in hypoglycemic events. Deglutethimide is indicated for the treatment of type 1 and type 2 diabetes in adults. For patients with type 1 diabetes, degludec insulin is used once daily (in combination with mealtime rapid-acting insulin); for patients with type 2 diabetes, degludec insulin can be used alone or in combination with oral hypoglycemic agents, GLP-1 analogs or mealtime insulin. Although it is important to make clinical judgments about patients (considering BMI and insulin resistance levels, etc.) when determining the initial dose, the recommended initial dose of degludec insulin for patients with type 2 diabetes who have not received insulin therapy is 10 units/day, based on the results of phase III clinical trials. Switching to Degludec insulin Clinical trials have confirmed that patients treated with other insulin regimens can switch to Degludec insulin, but blood glucose should be closely monitored and insulin dose may need to be adjusted during the switch. Switching from once-daily insulin to degludec insulin is usually done at a 1:1 dose ratio; if previously on a twice-daily insulin regimen, a 20% dose reduction is recommended. Of course, when switching from once-daily insulin to degludec insulin, a reduction in the dose of degludec insulin may also be considered if the patient has a low HbA1c level. In addition, the mealtime insulin dose should be adjusted to reduce the risk of hypoglycemia after switching to degludec insulin. Deglutethimide dose titration Dose adjustments can be made weekly to achieve individualized glycemic control goals. Treatment goals and insulin dose adjustments are based on the patient’s pre-breakfast FPG (or SMBG) level. The average FBG for the previous two days can be calculated and compared to the glycemic control target, and 2 units of basal insulin can be increased or decreased to achieve the treatment target. Dosing flexibility Deglutethim insulin is administered once daily, preferably at the same time of day. However, if sometimes it is not possible to inject at the same time, the timing of Deglucan insulin administration can be flexibly adjusted, and it has been shown to be safe to administer two doses no less than 8 hours apart. The flexible dosing of Deglutethimide (8-40 hours apart) does not affect its efficacy or safety when compared to glargine insulin given at the same time each day. If a patient experiences a missed dose of degludec insulin, he or she should be instructed to inject it as soon as possible and restart the previous once-daily dosing regimen. Two different sizes Many patients with type 2 diabetes may require high doses of insulin to cope with insulin resistance, often requiring multiple injections or increasing the volume of each injection, which can cause significant pain at the injection site. Deglucan insulin is available in two different sizes: 100 U/mL and 200 U/mL, both of which are bioequivalent, while the latter reduces the injection volume by half. Special Populations Deglutethimide is approved for use in elderly (≥65 years) patients, as well as for patients with renal or hepatic insufficiency. However, as with other insulins, intensive blood glucose monitoring should be performed when used in the special populations mentioned above. The safety and efficacy of Deglutethimide for use in children or adolescents under 18 years of age is currently being validated. In addition, there is no clinical experience with the use of Degludec insulin in pregnant women.